Companies › iECURE
1 active drug program in 1 registered trial: 1 Phase 3; Metabolic and endocrine; next expected readout Dec 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ECUR-506 Gene editing therapy delivering OTC gene | OTC | Phase 3 | Ornithine Transcarbamylase Deficiency | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06255782 | ECUR-506 | Phase 3 | Ornithine Transcarbamylase Deficiency | Metabolic and endocrine | Dec 2027 |
CAMP4 Therapeutics Ultragenyx Pharmaceutical Arcturus Therapeutics
Spur Therapeutics Yong Zhao, MD, PhD Grace Science Orchard Therapeutics BioLab Holdings
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.